Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PLX
stocks logo

PLX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
16.80M
-7.76%
0.055
+83.33%
18.70M
+84.91%
0.035
-61.11%
19.50M
+24.54%
0.040
-180%
Estimates Revision
The market is revising Upward the revenue expectations for Protalix BioTherapeutics, Inc. (PLX) for FY2025, with the revenue forecasts being adjusted by 2.62% over the past three months. During the same period, the stock price has changed by 13.64%.
Revenue Estimates for FY2025
Revise Upward
up Image
+2.62%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+25%
In Past 3 Month
Stock Price
Go Up
up Image
+13.64%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Protalix Biotherapeutics Inc (PLX.A) is 10.00, compared to its 5-year average forward P/E of 4.45. For a more detailed relative valuation and DCF analysis to assess Protalix Biotherapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
4.45
Current PE
10.00
Overvalued PE
20.11
Undervalued PE
-11.20

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.30
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.01
Undervalued EV/EBITDA
-0.41

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.96
Current PS
0.00
Overvalued PS
3.08
Undervalued PS
0.83
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

PLX News & Events

Events Timeline

(ET)
2025-11-13
06:54:47
Protalix Announces Q3 Earnings Per Share of 3 Cents, Below Consensus Estimate of 5 Cents
select
2025-10-17 (ET)
2025-10-17
07:05:41
Protalix and Chiesi Global Receive Negative CHMP Opinion for Elfabrio
select
2025-07-21 (ET)
2025-07-21
06:52:09
Protalix appoints Gilad Mamlok as CFO
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-21Benzinga
HC Wainwright & Co. Reaffirms Buy Rating for Protalix BioTherapeutics, Adjusts Price Target to $12

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies to improve trading outcomes.

  • Market Winning Tools: Benzinga Pro is designed to equip traders with the tools and information necessary to succeed in the markets daily.

[object Object]
Preview
9.0
11-03Globenewswire
Chiesi Global Rare Diseases and Protalix BioTherapeutics Request EMA Re-evaluation of Negative Opinion on Elfabrio (pegunigalsidase alfa) Four-Week Dosing Regimen in the EU

  • Re-examination Request: Chiesi Global Rare Diseases and Protalix BioTherapeutics have requested a re-examination of the negative opinion from the EMA regarding the proposed dosing regimen of Elfabrio (pegunigalsidase alfa) for Fabry disease, seeking to add a 2 mg/kg every 4 weeks option to the existing 1 mg/kg every 2 weeks regimen.

  • Safety Information: Elfabrio is associated with hypersensitivity reactions, including anaphylaxis, and patients are advised to have medical support available during administration. Clinical trials reported a significant incidence of infusion-associated reactions among treated patients.

  • About Fabry Disease: Fabry disease is a rare genetic disorder caused by a deficiency of the enzyme alpha-galactosidase A, leading to serious health complications. Early detection and treatment are crucial for managing symptoms and slowing disease progression.

  • Chiesi Group Overview: Chiesi is a biopharmaceutical company focused on innovative therapies for rare diseases and is committed to social and environmental responsibility, aiming for net-zero greenhouse gas emissions by 2035.

[object Object]
Preview
7.0
10-28PRnewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX

  • Investigation Announcement: Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Protalix BioTherapeutics and its executives, urging affected investors to reach out for assistance.

  • Negative Regulatory Opinion: Protalix and its partner, Chiesi Global Rare Diseases, received a negative opinion from the European Medicines Agency regarding a proposed dosing regimen for their drug Elfabrio, leading to a significant drop in Protalix's stock price.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Protalix Biotherapeutics Inc (PLX) stock price today?

The current price of PLX is 1.75 USD — it has increased 1.74 % in the last trading day.

arrow icon

What is Protalix Biotherapeutics Inc (PLX)'s business?

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.

arrow icon

What is the price predicton of PLX Stock?

Wall Street analysts forecast PLX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PLX is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Protalix Biotherapeutics Inc (PLX)'s revenue for the last quarter?

Protalix Biotherapeutics Inc revenue for the last quarter amounts to 17.85M USD, decreased -0.60 % YoY.

arrow icon

What is Protalix Biotherapeutics Inc (PLX)'s earnings per share (EPS) for the last quarter?

Protalix Biotherapeutics Inc. EPS for the last quarter amounts to 0.03 USD, decreased -25.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Protalix Biotherapeutics Inc (PLX)'s fundamentals?

The market is revising Upward the revenue expectations for Protalix BioTherapeutics, Inc. (PLX) for FY2025, with the revenue forecasts being adjusted by 2.62% over the past three months. During the same period, the stock price has changed by 13.64%.
arrow icon

How many employees does Protalix Biotherapeutics Inc (PLX). have?

Protalix Biotherapeutics Inc (PLX) has 207 emplpoyees as of December 05 2025.

arrow icon

What is Protalix Biotherapeutics Inc (PLX) market cap?

Today PLX has the market capitalization of 140.74M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free